Notably, CBFB-overexpression in MV4-11 cells conferred proliferative advantage and resistance to Ara-C (cytarabine), a widely-used first line clinical anti-leukemia drug (Fig. 6a, Supplementary Fig. 5a). This evidence concerns the gene CBFB and leukemia.